Cannabidivarin alleviates α‐synuclein aggregation via DAF ‐16 in Caenorhabditis elegans
The FASEB Journal · 2023
DOI: 10.1096/fj.202200278rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Fangru Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science and Technology, Changchun University of Science and Technology, Changchun, China. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Cannabinoids, Parkinson Disease, Caenorhabditis elegans Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Beijing National Laboratory for Molecular Sciences.
Abstract (Originalsprache)
Cannabidivarin (CBDV), a structural analog of cannabidiol (CBD), has received attention in recent years owing to its anticonvulsant property and potential for treating autism spectrum disorder. However, the function and mechanism of CBDV involved in the progression of Parkinson's disease (PD) remain unclear. In this work, we found that CBDV inhibited α‐synuclein (α‐syn) aggregation in an established transgenetic Caenorhabditis elegans ( C. elegans ). The phenolic hydroxyl groups of CBDV are critical for scavenging reactive oxygen species (ROS), reducing the in vivo aggregation of α‐syn and preventing DAergic neurons from 6‐hydroxydopamine (6‐OHDA)‐induced injury and degeneration. By combining multiple biophysical approaches, including nuclear magnetic resonance spectrometry, transmission electron microscopy and fibrillation kinetics assays, we confirmed that CBDV does not directly interact with α‐syn or inhibit the formation of α‐syn fibrils in vitro. Further cellular signaling investigation showed that the ability of CBDV to prevent oxidative stress, the accumulation of α‐syn and the degeneration of DAergic neurons was mediated by DAF‐16 in the worms. This study demonstrates that CBDV alleviates the aggregation of α‐syn in vivo and reveals that the phenolic hydroxyl groups of CBDV are critical for this activity, providing a potential for the development of CBDV as a drug candidate for PD therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Science and Technology, Changchun University of Science and Technology, Changchun, China.
- Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
- State Key Laboratory for Molecular Biology of Special Economic Animal, Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun, China.
- State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, China.
Förderung
- Beijing National Laboratory for Molecular Sciences
Zitieren
APA
Wang, F., Jin, T., Li, H., Long, H., Liu, Y., Jin, S., Lu, Y., Peng, Y., Liu, C., Zhao, L., & Wang, X. (2023). Cannabidivarin alleviates α‐synuclein aggregation via DAF ‐16 in Caenorhabditis elegans. The FASEB Journal. https://doi.org/10.1096/fj.202200278rr
Vancouver
Wang F, Jin T, Li H, Long H, Liu Y, Jin S, et al. Cannabidivarin alleviates α‐synuclein aggregation via DAF ‐16 in Caenorhabditis elegans. The FASEB Journal. 2023. doi:10.1096/fj.202200278rr
BibTeX
@article{Wang2023,
author = {Wang, Fangru and Jin, Ting and Li, Hongyuan and Long, Houfang and Liu, Ying and Jin, Sha and Lu, Yuyuan and Peng, Yinghua and Liu, Cong and Zhao, Lihui and Wang, Xiaohui},
title = {Cannabidivarin alleviates α‐synuclein aggregation via DAF ‐16 in Caenorhabditis elegans},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202200278rr}
}
EUVIMED